Restless Legs Syndrome and Iron: Ferritin Targets, Dopamine and the Augmentation Trap
Restless legs in the evening, an urge to move that cuts sleep apart. Behind restless legs syndrome there is often a brain iron deficiency that throws the dopamine system out of rhythm. Why the ferritin target is higher than most laboratories mark it, which medications can worsen RLS and why the once-celebrated dopamine agonists are now to be used with caution.
Restless legs syndrome is one of the most frequently overlooked sleep disorders, even though a central building block of its cause is measurable and well treatable: iron status. The leading explanation links a brain iron deficiency with a dysfunction of the dopaminergic system (Manconi 2021 in Nature Reviews Disease Primers). The tricky part: brain iron can be low even though the iron value in the blood looks unremarkable. This is why higher ferritin targets apply in RLS than for the general population; a ferritin above 75 to 100 ng/ml is the goal here, not just the anaemia threshold (Winkelman 2025 in the Journal of Clinical Sleep Medicine). And the second great lesson of recent years: the dopamine agonists once celebrated as standard can worsen RLS in the long term, the augmentation. First measure iron status, then check the triggers, then treat with care. In this spoke I lay out pathophysiology, diagnosis and treatment cleanly.
This spoke goes through it step by step: what RLS is and how common, the pathophysiology of brain iron and dopamine, the five diagnostic core criteria, iron diagnostics and the correct ferritin targets, the medications and factors that can trigger or worsen RLS, today's treatment logic with the shift away from the dopamine agonists, augmentation as the central warning, a PNI perspective on the system behind it, a reframe against widespread misconceptions and three concrete levers for the next conversation with your physician.
What restless legs syndrome is and how common it is
Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a sensorimotor disorder with an urgent need to move the legs, usually accompanied by uncomfortable sensations that are hard to describe. The symptoms begin or intensify at rest, improve with movement and typically occur in the evening and at night. It is precisely this temporal emphasis that makes RLS a sleep problem: the urge to move delays falling asleep and interrupts sleep.
According to a review in the Revue neurologique, about 2 to 3 percent of the population in Western countries are affected to a clinically relevant degree (Karroum 2008). RLS can be idiopathic, often with familial clustering and early onset, or occur secondarily as a consequence of other conditions, above all in iron deficiency, in pregnancy and in chronic kidney impairment (Gossard 2021 in Neurotherapeutics). Many affected people also show periodic limb movements during sleep, which can fragment sleep further.
RLS is not the same as nocturnal calf cramps and not the same as the inner restlessness of akathisia, in which the whole body urges, not only the legs. The key is the pattern: urge plus worsening at rest plus relief with movement plus evening emphasis. Whoever recognises this pattern can distinguish RLS from mix-ups.
The pathophysiology: brain iron and dopamine
The best-supported explanation today links two levels: a regional iron deficiency in the brain and a dysfunction of the dopaminergic system co-promoted by it. Dopamine needs iron: the enzyme tyrosine hydroxylase, the rate-limiting step of dopamine synthesis, is iron-dependent. If iron is missing in the right place, dopaminergic signalling goes out of balance. The circadian emphasis in the evening fits this, since dopaminergic activity fluctuates over the time of day.
Less ferritin and a disturbed transferrin receptor in dopaminergic cells
Human James Connor and colleagues examined, in 2004 in Neurology, brain tissue from autopsies of people with RLS and controls. In the neuromelanin-containing cells of the substantia nigra, a dopaminergic core region, they found in RLS reduced ferritin and an altered profile of the iron-management proteins, including a reduced transferrin receptor and a reduced activity of iron regulatory protein 1. The pattern points to a cellular iron depletion in exactly those cells that produce dopamine, despite in part normal iron values in the blood.
Connor JR, Wang XS, Patton SM, et al. Neurology. 2004;62(9):1563-7. doi:10.1212/01.wnl.0000123251.60485.ac · PMID: 15136682 [Pathophysiology]
Disturbed iron uptake at the blood-brain barrier in RLS
Human The same research group showed in 2011 in the journal Brain, using autopsy tissue, that iron transport at the interface between blood and brain is also altered. In the choroid plexus and in the brain microvessels they found in RLS changes in the iron-management proteins, including a reduced transferrin receptor in the microvessels. The authors conclude that the uptake of iron into the brain can be fundamentally disturbed in RLS. This explains why brain iron can be low while the blood iron value appears normal.
Connor JR, Ponnuru P, Wang XS, et al. Brain. 2011;134(Pt 4):959-68. doi:10.1093/brain/awr012 · PMID: 21398376 [Pathophysiology]
The large review in Nature Reviews Disease Primers summarises the state of knowledge: RLS is a complex disorder in which genetic predisposition, environmental factors and comorbidities act together. The pathophysiological hypotheses discussed are brain iron deficiency, dopaminergic dysfunction and altered adenosine and glutamate signalling pathways (Manconi 2021). Important for context: the mechanisms are not yet conclusively clarified; the picture of iron and dopamine is the best-supported but not the only explanation.
Diagnosis: five criteria, no blood test
RLS is a clinical diagnosis. There is no laboratory value that proves the disorder. The five internationally established core criteria are:
1. Urge to move
An urge to move the legs, usually accompanied by or caused by uncomfortable, often hard-to-describe sensations in the legs.
2. Rest worsens
The urge begins or intensifies during phases of rest or inactivity, for example while sitting or lying down.
3. Movement relieves
The urge improves partially or fully with movement such as walking or stretching, at least as long as the activity continues.
4. Evening and night emphasis
The symptoms occur in the evening or at night or are then more pronounced than during the day.
The fifth criterion is an exclusion criterion: the symptoms must not be explained solely by another condition or behaviour, for example by leg cramps, venous congestion, leg oedema or habitual foot tapping. It is important to distinguish from akathisia and from polyneuropathy, which can imitate RLS or even help trigger it (Karroum 2008). With every clinically relevant diagnosis, iron status, that is ferritin and transferrin saturation, belongs to the basic diagnostics, because low iron stores represent a treatable cause (Gossard 2021).
Iron diagnostics and the correct ferritin targets
This is where the most common mistake in practice lies. Many laboratories mark a ferritin value of 30 or 15 ng/ml as the lower normal limit. For RLS this is misleading, because the disorder is linked to a regional brain iron deficiency that can occur before a classic iron deficiency anaemia becomes visible. This is why separate, higher target values apply.
Ferritin target above 100 ng/ml, therapy from 75 ng/ml or below
Guideline The guideline of the American Academy of Sleep Medicine (Winkelman 2025 in the Journal of Clinical Sleep Medicine) formulates as a good practice statement: in all patients with clinically relevant RLS, iron status should be assessed regularly, including ferritin and transferrin saturation. Iron can be considered when serum ferritin is at or below 75 ng/ml or transferrin saturation is below 20 percent, with the goal of raising ferritin above 100 ng/ml. If ferritin is between 75 and 100 ng/ml, intravenous administration is favoured. In children a threshold of below 50 ng/ml applies. The guideline emphasises explicitly that these values differ from the recommendations for the general population.
Winkelman JW, Berkowski JA, DelRosso LM, et al. J Clin Sleep Med. 2025;21(1):137-152. doi:10.5664/jcsm.11390 · PMID: 39324694 [Guideline]
Practical note from the guideline on measurement: iron should ideally be determined in the morning, and for at least 24 hours before the blood draw no iron-containing supplements or iron-rich meals should be taken, otherwise values may be distorted. Ferritin is moreover an acute phase protein and can appear falsely high during inflammation, which is why transferrin saturation is assessed alongside it.
Iron treatment algorithm for RLS, evidence- and consensus-based
Guideline The International Restless Legs Syndrome Study Group published in 2018 in Sleep Medicine a task force report on iron treatment (Allen 2018). Of 299 reviewed papers, 31 met the inclusion criteria. Four studies in adults received the highest evidence class, three of them on intravenous ferric carboxymaltose. Conclusion: ferric carboxymaltose (1000 mg) is effective for the treatment of moderate to severe RLS at a serum ferritin below 300 ng/ml and can be used as a first-line option in adults. Oral iron (about 65 mg elemental iron) may possibly help at a ferritin at or below 75 ng/ml.
Allen RP, Picchietti DL, Auerbach M, et al. Sleep Med. 2018;41:27-44. doi:10.1016/j.sleep.2017.11.1126 · PMID: 29425576 [Guideline]
"My ferritin is normal, so it cannot be an iron issue." A ferritin of 40 ng/ml counts as normal in many laboratory reports but lies well below the RLS target range. A normal blood value does not rule out a brain iron deficiency, as the autopsy data from Connor 2004 and 2011 suggest. In RLS it is worth a second look at the concrete numerical value, not just at the marking of normal or abnormal.
Medications and factors that can worsen RLS
Before any RLS medication is started, the review of aggravating factors belongs at the beginning. The AASM guideline (Winkelman 2025) names, as the first step of treatment, explicitly addressing such factors: alcohol, caffeine, antihistaminergic, serotonergic and antidopaminergic medications as well as untreated obstructive sleep apnoea.
Antidepressants
Many serotonergic antidepressants (SSRIs, SNRIs) and mirtazapine can trigger or intensify RLS symptoms. Never stop on your own; weigh it up medically.
Antidopaminergic substances
Many antipsychotics and the antiemetic metoclopramide block dopamine receptors and can unmask or intensify RLS.
Sedating antihistamines
First-generation antihistamines such as diphenhydramine, often in over-the-counter sleep aids, are considered an aggravating factor.
Lifestyle and accompanying factors
Alcohol, caffeine in the afternoon and evening, and untreated sleep apnoea can intensify the symptoms.
This list is not a call to drop medications. Antidepressants and antipsychotics often fulfil important functions. It is about recognising possible triggers and, together with the treating physician, weighing benefit and risk, for example through dose adjustment or a switch to a substance with a more favourable profile.
Today's treatment logic and the shift
The medication treatment of RLS has undergone a clear change of course in recent years. For a long time dopamine agonists were considered standard. Today a different approach is in the foreground.
From dopamine agonists as standard to alpha-2-delta ligands in front
Guideline The older 2012 AASM guideline (Aurora in Sleep) still listed pramipexole and ropinirole as a standard recommendation. The updated 2025 AASM guideline (Winkelman) has revised this fundamentally: it makes strong recommendations for gabapentin enacarbil, gabapentin and pregabalin, that is for the alpha-2-delta ligands. For intravenous ferric carboxymaltose with suitable iron status there is likewise a strong recommendation. At the same time the guideline advises against the routine use of pramipexole, ropinirole, rotigotine and levodopa and explicitly recommends against cabergoline. The background is above all the risk of augmentation.
Winkelman JW, et al. J Clin Sleep Med. 2025;21(1):137-152. doi:10.5664/jcsm.11390 · PMID: 39324694 · cf. Aurora RN, et al. Sleep. 2012;35(8):1039-62. doi:10.5665/sleep.1988 · PMID: 22851801 [Guideline]
Simplified, today's logic can be described like this: iron status first. If the stores are low (ferritin at or below 75 ng/ml or transferrin saturation below 20 percent), iron therapy is the cause-oriented building block, oral or, with suitable status, intravenous. If the iron stores are adequate, the alpha-2-delta ligands gabapentin, gabapentin enacarbil or pregabalin move to the front (Winkelman 2025). According to current data they cause no augmentation, but they can produce tiredness, dizziness and drowsiness. Dopamine agonists and opioids remain reserved for selected, often more severe or treatment-refractory cases and belong in specialist hands.
Augmentation: the central warning
Augmentation is the most important long-term complication of dopaminergic therapy and the reason for the change of course. It means a paradoxical worsening under the treatment that is actually effective.
What characterises augmentation
Review In a review in Nature Reviews Neurology, Trenkwalder and colleagues describe augmentation as the central problem of long-term therapy with dopamine agonists (Trenkwalder 2015). Its hallmarks are: the symptoms occur earlier in the day than before, they become more intense, the symptom-free latency at rest shortens, and the symptoms can spread to previously unaffected body regions such as the arms. Paradox: a dose increase often worsens the augmentation further instead of helping. This is exactly why the choice of first-line therapy is more cautious today. If augmentation is suspected, iron status should be checked again (Gossard 2021).
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Nat Rev Neurol. 2015;11(8):434-45. doi:10.1038/nrneurol.2015.122 · PMID: 26215616 [Mechanism review]
Anyone already taking a dopamine agonist who notices that the symptoms start earlier, become stronger or migrate into the arms should have it clarified promptly with a physician whether augmentation is present. Stopping or switching dopaminergic medications belongs in experienced hands, because a transitional phase can bring a temporary worsening.
The PNI perspective: the system behind the symptom
In clinical psychoneuroimmunology I look not only at the symptom in the leg but at the system that shapes the iron and neurotransmitter balance. RLS is a good example of this: a local brain iron deficiency, a dopaminergic system, the circadian rhythm and sleep mesh together. Four lenses help to order the picture.
Iron metabolism
Iron is a cofactor of dopamine synthesis. Low stores, blood loss (such as heavy menstruation), pregnancy, impaired absorption or chronic inflammation can strain the iron balance. The ferritin value is the measurable window, in the RLS context with a higher target value.
Dopaminergic system
The iron-dependent dopaminergic signalling explains the circadian evening emphasis. Substances that block dopamine can intensify RLS, which underscores the importance of the medication history.
Sleep and circadian rhythm
RLS and sleep form a vicious circle: the urge to move disturbs sleep, sleep deprivation and disturbed rhythms can intensify the symptoms. Sleep hygiene and the treatment of a sleep apnoea are therefore more than an afterthought.
Comorbidities
RLS occurs more frequently in iron deficiency, kidney impairment and in pregnancy and is associated with further internal and neurological comorbidities (Manconi 2021). The search for secondary causes is part of every workup.
What does not work
What does not work: blindly swallowing a high-dose iron supplement from the internet without knowing the iron status. Iron overload has its own risks, and not every RLS case is iron-dependent. What also does not work: keeping on increasing the dose of a dopamine agonist when the symptoms grow, which is often precisely the sign of augmentation. And what does not work: deriving the diagnosis of RLS from a single laboratory value or from periodic limb movements alone. RLS remains a clinical diagnosis based on the five criteria. The clean way is the other way round: first measure and contextualise, then treat in a targeted and cause-oriented way, then observe the course.
Three levers for the next conversation
Ask for the concrete ferritin value
Have ferritin and transferrin saturation given to you not just as normal or abnormal but as a concrete number. Ask whether the value lies in the RLS target range (ferritin above 75 to 100 ng/ml). Ask for a measurement in the morning and without iron intake in the 24 hours beforehand.
Go through the medication list
Bring your complete medication list, including over-the-counter sleep aids and antihistamines. Ask specifically whether any of them could worsen RLS and whether an adjustment makes sense. Do not stop anything on your own.
With ongoing dopaminergic therapy, think of augmentation
If you are already taking pramipexole, ropinirole or rotigotine and the symptoms occur earlier, more strongly or in the arms, raise it actively. This can be augmentation and should be evaluated by a specialist before the dose is increased.
Calm legs, calm sleep
The goal is not a perfect laboratory value but legs that come to rest in the evening, and sleep that holds. The path to it begins with the right question about iron status and a treatment that addresses the cause instead of only dampening it briefly.
Frequently asked questions about restless legs syndrome and iron
What does restless legs syndrome have to do with iron?
A great deal. The leading explanation of restless legs syndrome (RLS) today is a brain iron deficiency that promotes a dysfunction of the dopaminergic system. Connor and colleagues showed in 2004 in Neurology, using autopsy brain tissue, that the neuromelanin-containing cells of the substantia nigra in RLS have less ferritin and an altered transferrin receptor. In 2011 the same group showed in the journal Brain that iron transport at the blood-brain barrier is also disturbed. Important: brain iron can be reduced even though the serum iron value looks normal. This is why ferritin targets in RLS are set higher than for the general population. It also explains why iron therapy can help some affected people when iron stores are low.
Which ferritin value should be aimed for in restless legs syndrome?
The target values are considerably higher than the usual lower laboratory limits. According to the AASM guideline (Winkelman 2025 in the Journal of Clinical Sleep Medicine) and the IRLSSG task force report (Allen 2018 in Sleep Medicine): iron therapy can be considered when serum ferritin is at or below 75 ng/ml or transferrin saturation is below 20 percent. The goal is to raise ferritin above 100 ng/ml. If ferritin is between 75 and 100 ng/ml, the guideline favours intravenous iron. These values are not the same as the thresholds for a classic iron deficiency anaemia. Iron should be measured in the morning and at least 24 hours after the last iron intake, otherwise values may be distorted. Iron therapy does not replace medical examination and belongs in medical hands.
How does restless legs syndrome present and how is it diagnosed?
RLS is a clinical diagnosis based on five core criteria: an urge to move the legs, usually accompanied by uncomfortable sensations; onset or worsening at rest; relief through movement; intensification in the evening or at night; and the symptoms are not solely explained by another condition. There is no blood test that proves RLS. It is important to distinguish it from nocturnal calf cramps, from polyneuropathy, from akathisia (inner restlessness of the whole body) and from venous leg complaints. With every clinically relevant RLS diagnosis, iron status (ferritin and transferrin saturation) should be assessed, because low iron stores are a treatable cause. Periodic limb movements during sleep are common but not proof of RLS.
Which medications can trigger or worsen restless legs syndrome?
Several commonly prescribed drug classes can trigger or intensify RLS symptoms. These include many antidepressants, above all serotonergic ones (SSRIs, SNRIs) and mirtazapine, as well as antidopaminergic substances such as many antipsychotics and the antiemetic metoclopramide, plus sedating first-generation antihistamines (for example diphenhydramine). Alcohol, caffeine and untreated obstructive sleep apnoea are also considered aggravating factors. The AASM guideline (Winkelman 2025) names, as the first step of treatment, checking such aggravating factors explicitly and reducing them where possible. Stopping medications on your own is not a good idea. Always discuss possible triggers with a clinician so that benefit and risk can be weighed.
Why are dopamine agonists no longer the first choice in restless legs syndrome?
Because of augmentation. Dopamine agonists such as pramipexole, ropinirole and rotigotine often work very well at first, but with longer use they can paradoxically worsen RLS: symptoms appear earlier in the day, become more intense and sometimes spread to the arms or the trunk. That is augmentation. While the older 2012 AASM guideline (Aurora) still listed pramipexole and ropinirole as standard, the updated 2025 AASM guideline (Winkelman) now advises against the routine use of these dopamine agonists and explicitly recommends against cabergoline. If dopamine agonists are used at all, then at a low dose and for a short time. The decision belongs in specialist hands.
What now stands at the start of medication treatment?
With adequate iron status, the alpha-2-delta ligands gabapentin, gabapentin enacarbil and pregabalin move to the foreground. The 2025 AASM guideline (Winkelman) makes strong recommendations for gabapentin enacarbil, gabapentin and pregabalin respectively. According to current data these substances cause no augmentation and no impulse control problem, but they can cause tiredness, dizziness and drowsiness. If iron stores are low (ferritin at or below 75 ng/ml or transferrin saturation below 20 percent), iron therapy stands at the start as a cause-oriented building block. With suitable iron status, intravenous ferric carboxymaltose carries a strong recommendation. Which sequence makes sense in an individual case is decided by the treating physician.
Does an iron infusion help in restless legs syndrome?
With suitable iron status, intravenous iron can help. The IRLSSG task force report (Allen 2018 in Sleep Medicine) rated intravenous ferric carboxymaltose (1000 mg) at a serum ferritin below 300 ng/ml as effective and as a possible first-line option in adults with moderate to severe RLS. The 2025 AASM guideline also makes a strong recommendation for intravenous ferric carboxymaltose with suitable iron status. Oral iron (about 65 mg elemental iron) may possibly help at a ferritin at or below 75 ng/ml. Giving iron without first determining ferritin and transferrin saturation is not sensible, because iron overload carries its own risks. This belongs in medical hands.
What can I do myself, without medication?
Several non-pharmacological building blocks can support, even if the evidence for them is limited. These include reducing aggravating factors such as alcohol, caffeine especially in the afternoon and evening, critically reviewing triggering medications under medical guidance, consistent sleep hygiene and treating any sleep apnoea. Some affected people report relief through movement, stretching, massage or warm baths. The most important cause-oriented step remains assessing and, where appropriate, replenishing the iron stores. Important: persistent or severe symptoms belong in medical evaluation, also so as not to overlook secondary causes such as iron deficiency, kidney impairment, pregnancy or a polyneuropathy.
More from the cluster "Treating sleep disorders holistically"
- Pillar: Sleep disorders holistically
- Spoke 12: Iron, thyroid and sleep
- Spoke 11: Restless legs syndrome and iron (you are here)
Connections to other topics
The pillar places restless legs syndrome within the overall picture of sleep disorders, from sleep hygiene through circadian rhythms to organic causes.
Goes deeper into iron metabolism, ferritin interpretation and the interplay with the thyroid, which is also relevant for RLS and sleep.
Sources and further reading
- Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025;21(1):137-152. doi:10.5664/jcsm.11390 · PMID: 39324694 [Guideline]
- Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27-44. doi:10.1016/j.sleep.2017.11.1126 · PMID: 29425576 [Guideline]
- Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004;62(9):1563-7. doi:10.1212/01.wnl.0000123251.60485.ac · PMID: 15136682 [Pathophysiology]
- Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain. 2011;134(Pt 4):959-68. doi:10.1093/brain/awr012 · PMID: 21398376 [Pathophysiology]
- Manconi M, Garcia-Borreguero D, Schormair B, et al. Restless legs syndrome. Nat Rev Dis Primers. 2021;7(1):80. doi:10.1038/s41572-021-00311-z · PMID: 34732752 [Review]
- Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome - current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434-45. doi:10.1038/nrneurol.2015.122 · PMID: 26215616 [Mechanism review]
- Gossard TR, Trotti LM, Videnovic A, St Louis EK. Restless Legs Syndrome: Contemporary Diagnosis and Treatment. Neurotherapeutics. 2021;18(1):140-155. doi:10.1007/s13311-021-01019-4 · PMID: 33880737 [Review]
- Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-62. doi:10.5665/sleep.1988 · PMID: 22851801 [Guideline]
- Comella CL. Treatment of restless legs syndrome. Neurotherapeutics. 2014;11(1):177-87. doi:10.1007/s13311-013-0247-9 · PMID: 24363103 [Review]
- Karroum E, Konofal E, Arnulf I. Restless-legs syndrome. Rev Neurol (Paris). 2008;164(8-9):701-21. doi:10.1016/j.neurol.2008.06.006 · PMID: 18656214 [Review]